ADCY9

Across TCGA pan-cancer cohorts, ADCY9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADCY9 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ADCY9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ADCY9 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where ADCY9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.890	0.602	<.001	33	view →
HNSC	OS	Quartile	All	0.928	0.628	.003	19	view →
PDAC	DFS	Tertile	III,IV	0.708	0.157	.010	10	view →
UCEC	DFS	Tertile	All	0.695	1.000	.010	8	view →
CCRCC	OS	Tertile	All	1.000	0.621	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADCY9–LUAD (OS)

Open the LUAD breakdown →